The above evidence confirms that m6A methylation and various metabolites can cause TME immunosuppression and immune evasion by regulating PD-L1 levels and affecting various immune cells, providing a new angle to solve the difficulties of cancer immunotherapy. The gene discussed is CD274; the disease is cancer.